.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Johnson and Johnson
Harvard Business School
Fish and Richardson
Deloitte
US Department of Justice
Cerilliant
Fuji
UBS

Generated: November 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,303,651

« Back to Dashboard

Claims for Patent: 4,303,651

Title: Heparin fragments having selective anticoagulation activity
Abstract:Heparin fragments having selective anticoagulation activity having 14-18 sugar units, the disaccharide unit L-iduronosyl-2-O-sulphate-N-sulpho-U-glucosamine-6-O-sulphate being the main component, and where unsulphated L-iduronic acid is in a position situated 3-5 sugar units from the unreducing terminal. Pharmaceutical compositions containing such heparin fragments. Processes for the preparation of the heparin fragments.
Inventor(s): Lindahl; Ulf P. F. (Uppsala, SE), Backstrom; Gudrun E. (Alunda, SE), Thunberg; John Y. L. (Uppsala, SE), Fransson; Lars-Ake (Lund, SE), Andersson; Lars-Olov (Knivsta, SE), Holmer; Erik Y. (Bromma, SE), Sandberg; Inga H. (Sollentuna, SE), Soderstrom; Ewa G. (Saltsjobaden, SE)
Assignee: Kabi AB (Stockholm, SE)
Application Number:06/109,936
Patent Claims: 1. Heparin fragments having 14-18 sugar units, wherein the main component is the disaccharide unit L-iduronosyl-2-O-sulphate-N-sulpho-D-glucosamine-6-O-sulphate, and where unsulphated L-iduronic acid is in a position situated 3-5 sugar units from the unreducing terminal and is followed by a unit selected from the group consisting of N-sulpho-D-glucosamine sulphate and N-acetyl-glucosamine in sulphated and unsulphated form.

2. Heparin fragments having the structure (U-G).sub.n -I-G-(U-G).sub.m where n is 1 or 2 and m is 5 or 6, I is unsulphated L-iduronic acid, U is L-iduronic acid-2-O-sulphate, and G is N-sulpho-D-glucosamine-6-O-sulphate.

3. Pharmaceutical compositions for preventative treatment or treatment of arterial thrombosis containing heparin fragments having selective anticoagulation activity and containing 14-18 sugar units, wherein the main component is the disaccharide unit L-iduronosyl-2-O-sulphate-N-sulpho-D-glucosamine-6-O-sulphate, and where unsulphated L-iduronic acid is in a position situated 3-5 sugar units from the unreducing terminal and is followed by a unit selected from the group consisting of N-sulpho-D-glucosamine sulphate and N-acetyl-glucosamine in sulphated and unsulphated form in an amount sufficient for anticoagulation activity; and a pharmaceutical carrier.

4. Pharmaceutical composition for preventative treatment or treatment of arterial thrombosis containing heparin fragments of the structure (U-G).sub.n -I-G-(U-G).sub.m where n is 1 or 2 and m is 5 or 6, I is unsulphated L-iduronic acid, U is L-iduronic acid-2-O-sulphate and G is N-sulpho-D-glucosamine-6-O-sulphate in an amount sufficient for anticoagulation activity; and a pharmaceutical carrier.

5. The composition of claim 3 or 4 wherein said carrier is water.

6. The composition of claim 3 or 4 which is in the form of an ointment.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Daiichi Sankyo
Cantor Fitzgerald
Fuji
Cipla
QuintilesIMS
Farmers Insurance
US Department of Justice
Chubb
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot